prikaz prve stranice dokumenta Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study
  Preuzmi
PDF 471.61 KB
Znanstveni rad - Izvorni znanstveni rad
Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study
Antibiotics, 11 (2022), 2; 176. https://doi.org/10.3390/antibiotics11020176
Papst, Lea; Luzzati, Roberto; Carević, Biljana; Tascini, Carlo; Gorišek Miksić, Nina; Vlahović Palčevski, Vera; Djordjevic, Zorana M.; Simonetti, Omar; Sozio, Emanuela; Lukić, Milica; Stevanović, Goran; Petek, Davor; Beović, Bojana

Povezani objekti
COVID-19 (zbirka 2.) | Virtualna zbirka
Citirajte ovaj rad

Papst, L., Luzzati, R., Carević, B., Tascini, C., Gorišek Miksić, N., Vlahović Palčevski, V. ... Beović, B. (2022). Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study. Antibiotics, 11. (2). doi: 10.3390/antibiotics11020176

Papst, Lea, et al. "Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study." Antibiotics, vol. 11, br. 2, 2022. https://doi.org/10.3390/antibiotics11020176

Papst, Lea, Roberto Luzzati, Biljana Carević, Carlo Tascini, Nina Gorišek Miksić, Vera Vlahović Palčevski, Zorana M. Djordjevic, et al. "Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study." Antibiotics 11, br. 2 (2022). https://doi.org/10.3390/antibiotics11020176

Papst, L., et al. (2022) 'Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study', Antibiotics, 11(2). doi: 10.3390/antibiotics11020176

Papst L, Luzzati R, Carević B, Tascini C, Gorišek Miksić N, Vlahović Palčevski V, i sur.. Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study. Antibiotics [Internet]. 28.01.2022. [pristupljeno 05.12.2024.];11(2). doi: 10.3390/antibiotics11020176

L. Papst, et al., "Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study", Antibiotics, vol. 11, br. 2, Siječanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:087238. [Citirano: 05.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:087238
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Antimicrobial Use in Hospitalised Patients with COVID-19: An International Multicentre Point-Prevalence Study
AutorLea Papst
AutorRoberto Luzzati
AutorBiljana Carević
AutorCarlo Tascini
AutorNina Gorišek Miksić
AutorVera Vlahović Palčevski
AutorZorana M. Djordjevic
AutorOmar Simonetti
AutorEmanuela Sozio
AutorMilica Lukić
AutorGoran Stevanović
AutorDavor Petek
AutorBojana Beović
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Klinička farmakologija s toksikologijom
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (engleski)
Studies suggest that the incidence of coinfections in patients with the coronavirus disease 2019 (COVID-19) is low, but a large number of patients receive antimicrobials during hospitalisation. This may fuel a rise in antimicrobial resistance (AMR). We conducted a multicentre point-prevalence survey in seven tertiary university hospitals (in medical wards and intensive care units) in Croatia, Italy, Serbia and Slovenia. Of 988 COVID-19 patients, 521 were receiving antibiotics and/or antifungals (52.7%; range across hospitals: 32.9–85.6%) on the day of the study. Differences between hospitals were statistically significant (χ2 (6, N = 988) = 192.57, p < 0.001). The majority of patients received antibiotics and/or antifungals within 48 h of admission (323/521, 62%; range across hospitals: 17.4–100%), their most common use was empirical (79.4% of prescriptions), and pneumonia was the main indication for starting the treatment (three-quarters of prescriptions). The majority of antibiotics prescribed (69.9%) belonged to the “Watch” group of the World Health Organization AWaRe classification. The pattern of antimicrobial use differed across hospitals. The data show that early empiric use of broad-spectrum antibiotics is common in COVID-19 patients, and that the pattern of antimicrobial use varies across hospitals. Judicious use of antimicrobials is warranted to prevent an increase in AMR.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaAntibiotics
Brojčani podacivol. 11, br. 2, 176
e-ISSN2079-6382
DOIhttps://doi.org/10.3390/antibiotics11020176
URN:NBNurn:nbn:hr:184:087238
Datum objave publikacije2022-01-28
URL dokumentahttps://www.mdpi.com/2079-6382/11/2/176
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-09-22 12:11:38